Related by context. Frequent words. (Click for all words.) 72 unblinded 65 Phase 2b study 62 dose escalation 61 clinical trial 61 Phase Ib 60 Phase IIa trial 60 Phase III clinical 60 Phase 1b 59 Phase III pivotal 59 Phase 2a 59 Phase IIb 58 Phase IIb trial 58 daclizumab 57 multiple ascending dose 57 Phase 2b trial 57 Phase IIb clinical 57 Phase 2b clinical 56 sunitinib 56 Phase III trials 56 Phase IIa clinical 56 primary endpoint 56 randomized clinical trials 56 Phase 2a clinical 56 placebo controlled 56 randomized trials 56 ACTEMRA 56 ASA# 55 Phase IIa 55 mg dose 55 tolerability 55 pivotal Phase III 55 Phase III 55 randomized Phase 55 Phase 2b 54 blind randomized placebo 54 rivaroxaban 54 elesclomol 54 randomized controlled 54 ZYBRESTAT 54 Opexa 54 raltegravir 54 clinical trials 53 randomized clinical 53 non inferiority 53 prospective randomized 53 Vectibix 53 Zerenex 53 dosing 53 randomized placebo controlled 53 pivotal Phase 53 MDV# 53 dose escalation study 53 clinical endpoints 53 primary endpoints 53 efficacy 53 ISIS # 53 multicenter 53 ALTU 53 tolerability profile 52 Phase III clinical trials 52 secondary endpoint 52 denosumab 52 rosiglitazone 52 multicenter study 52 Qnexa 52 ticagrelor 52 T DM1 52 JANUVIA 52 ONGLYZA 52 dose limiting toxicities 52 PRX # 52 LibiGel 52 mipomersen 52 randomized controlled trials 52 picoplatin 52 Hematide 52 bevacizumab 51 LymphoStat B 51 pharmacokinetic 51 randomized double 51 ofatumumab 51 double blind placebo 51 certolizumab pegol 51 perifosine 51 meta analyzes 51 dosing regimens 51 sitagliptin 51 ACTOS 51 pralatrexate 51 randomized 51 pharmacodynamics 51 Entereg 51 pemetrexed 51 RG# [001] 51 primary efficacy endpoint 51 FOLOTYN 51 pioglitazone 51 monotherapy 51 maraviroc 51 TMC# [001] 51 observational studies